PIPELINE OVERVIEW
NanoMab has a pipeline of five products for the treatment of a range of metastatic cancers with the first two assets having undergone three separate early phase I studies in China. Phase 2 clinical trials for NM-01 have commenced in the UK whilst NM-02, 03, 04, and 05 have been strategically out-licensed for development to key players in the biotech industry.
- NM-01 (PD-L1 Lung Cancer, diagnostics)
- NM-02 (HER-2 positive Breast Cancer and Gastric Cancer, diagnostics and therapeutics)
- NM-03 (HER2 negative Breast Cancer, diagnostics and therapeutics)
- NM-04 (Colorectal and Cervical Cancer, diagnostics and therapeutics)
- NM-05 (Pan-cancer, diagnostics and therapeutics)
